[Genetic Counselor]

The outlook for alpha-thalassemia depends on the type.
Silent carriers and people with alpha-thalassemia trait have a normal life expectancy and do not need ongoing monitoring. Knowing their status matters mainly for family planning, for avoiding unnecessary iron treatment, and for sharing the information with relatives, who may wish to be tested too.
Most people with deletion-type hemoglobin H disease live full, active lives with a normal or near-normal life expectancy. Forms caused by gene changes other than deletions are usually more severe and need closer care. Over time, the main concerns are iron build-up, gallstones, an enlarged spleen, and anemia that worsens during illness or pregnancy. With regular check-ups, most of these can be picked up early and managed.
Children who survive hemoglobin Bart’s hydrops fetalis after treatment in the womb need lifelong transfusion care or a stem cell transplant. Some have growth or developmental differences, or birth differences of the genital and urinary organs, and they need care from an experienced team.
Recommended monitoring for hemoglobin H disease includes:
• Blood counts: every 6 to 12 months, and during any illness with fever
• Growth and development in children: every 6 to 12 months
• Iron levels: a ferritin blood test once a year, with a specialized magnetic resonance imaging scan of the liver if ferritin is raised, to measure the actual iron stored and guide chelation
• Spleen and gallbladder: checking for an enlarged spleen and for gallstones, especially if abdominal pain develops
• Pregnancy: closer monitoring, since anemia often worsens and transfusions may be needed
• Regular transfusion or chelation: where needed, heart, liver, and hormone checks similar to those used in transfusion-dependent beta-thalassemia
For women carrying a baby with hemoglobin Bart’s hydrops fetalis, the mother also needs careful monitoring. This condition raises her risk of high blood pressure in pregnancy (preeclampsia), bleeding, and a difficult delivery. Early diagnosis, ideally in the first trimester, gives families more time and more choices.
Staying connected with a hematologist and a genetic counselor helps families make informed decisions for their own health and for future pregnancies.

[Genetic Counselor]

Signs of alpha-thalassemia depend on how many of the four alpha-globin genes are affected.

• Silent carrier and alpha-thalassemia trait These individuals are healthy. Blood counts may show slightly small, pale red blood cells, sometimes with a mild anemia. Most people only find out through routine blood tests, pregnancy screening, or when a relative is diagnosed.
• Hemoglobin H disease Symptoms vary a great deal. Some individuals have a mild anemia and live normally. Others have tiredness, pale skin, mild yellowing of the skin and eyes (jaundice), an enlarged spleen, and gallstones. A key feature is sudden drops in hemoglobin, called hemolytic crises, often triggered by fever, infection, pregnancy, or certain medicines. Forms caused by gene changes rather than deletions tend to be more severe, and some children need regular blood transfusions.
• Hemoglobin Bart’s hydrops fetalis This is usually picked up on pregnancy ultrasound. The baby develops severe anemia before birth, leading to fluid build-up around the body, an enlarged heart, liver, and spleen, and a thickened placenta. Without treatment during pregnancy, it is usually fatal before or shortly after birth.

Diagnosis usually begins with a complete blood count, which shows small, pale red blood cells. The next step is a hemoglobin analysis test, such as high-performance liquid chromatography or electrophoresis. This test is very good at finding beta-thalassemia trait, but it has an important limitation: in alpha-thalassemia trait, the results are usually normal. This means a person can be told their thalassemia screen is “normal” and still carry alpha-thalassemia. This matters in India, where routine screening is designed mainly around beta-thalassemia.

In hemoglobin H disease, the hemoglobin analysis shows hemoglobin H, and a special stain of the blood shows characteristic clumps inside red blood cells. In newborns, hemoglobin Bart’s can be measured at birth.
Confirmation comes from DNA testing of the HBA1 and HBA2 genes. This usually starts by checking for common deletions, then gene sequencing and deletion analysis if needed. When red blood cells are small and pale but iron levels and hemoglobin analysis are normal, DNA testing for alpha-thalassemia is the right next step. It also avoids giving iron tablets to people who do not need them, as extra iron can be harmful.

[Genetic Counselor]

Alpha-thalassemia is a genetic condition in which the body makes too little of a protein called alpha-globin. Alpha-globin is one of the two building blocks of hemoglobin, the molecule inside red blood cells that carries oxygen around the body. When alpha-globin is in short supply, red blood cells come out smaller, paler, and more fragile than usual, and this can lead to anemia, a shortage of healthy red blood cells.

Hemoglobin in adults is made of two alpha-globin chains paired with two beta-globin chains. Unlike beta-globin, which is made from a single gene, alpha-globin is made from four gene copies. Every person normally has two alpha-globin genes, called HBA1 and HBA2, sitting side by side on each copy of chromosome 16. Since we inherit one chromosome 16 from each parent, that adds up to four working alpha-globin genes in total.

In most people with alpha-thalassemia, one or more of these four genes is missing, usually because a small piece of DNA has been deleted. Less often, a gene is present but carries a harmful change that stops it working properly. The more genes that are missing or not working, the less alpha-globin the body can make, and the more severe the condition:

• One gene affected: a silent carrier, usually with no signs at all
• Two genes affected: alpha-thalassemia trait, usually a very mild anemia with no symptoms
• Three genes affected: hemoglobin H disease, a lifelong anemia that ranges from mild to severe
• All four genes affected: hemoglobin Bart’s hydrops fetalis, a severe condition that begins before birth

A useful way to picture this is a factory with four machines making the same part. Losing one machine barely changes output. Losing two slows things a little. Losing three causes real shortages. Losing all four stops production altogether.

When alpha-globin runs short, the leftover partner chains have nothing to pair with. They clump together into abnormal forms of hemoglobin, called hemoglobin H in children and adults and hemoglobin Bart’s before birth. These forms do not deliver oxygen well and make red blood cells break down early.

Alpha-thalassemia is not caused by anything a parent did during pregnancy, and it cannot be caught from another person. It comes entirely from the alpha-globin genes a child inherits.

[Genetic Counselor]

Most cancers in people with Li-Fraumeni syndrome are treated in the standard way for that cancer type. The difference is that doctors also try to lower the chance of a new cancer in the future. Knowing the diagnosis before treatment starts helps the care team make these choices.
–Radiation is avoided where possible
–Breast cancer surgery
–Chemotherapy
–Fewer radiation-based scans

Some steps can also lower risk before cancer develops:
–Risk-reducing breast surgery
–Colonoscopy
–Healthy habits
-Avoid tobacco in all forms, limit alcohol, protect the skin from strong sun, and reduce contact with workplace chemicals known to cause cancer. The effects of these exposures may add to the genetic risk.

Li-Fraumeni syndrome is a lifelong condition with a high cancer risk, and it would be wrong to suggest otherwise. But the outlook has changed. With early diagnosis, regular screening, and careful treatment choices, many cancers are now found early and treated successfully, and many people with Li-Fraumeni syndrome go on to study, work, raise families, and live full lives.

[Genetic Counselor]

Cancer screening (also called surveillance) is the most important part of care in Li-Fraumeni syndrome. The goal is to find cancers early, when they are smaller and easier to treat, and often before they cause symptoms.

From birth to age 18

–Full physical examination every 3–4 months
–Ultrasound of the abdomen and pelvis every 3–4 months
–Whole-body magnetic resonance imaging once a year
–Brain magnetic resonance imaging once a year

From age 18 onwards

–Physical examination every 6 months
–Whole-body and brain magnetic resonance imaging once a year
–Ultrasound of the abdomen and pelvis once a year
–Breast checks for women
–Upper endoscopy and colonoscopy every 2–5 years from age 25
–Skin examination once a year from age 18

Additional checks, depending on family history
A clinical geneticist can help families plan a practical, coordinated schedule.

[Genetic Counselor]

Li-Fraumeni syndrome follows what is called autosomal dominant inheritance.

We all carry two copies of each gene, one from each parent. A single faulty copy of TP53 is enough to cause the condition. When a parent has Li-Fraumeni syndrome, each child has a 1-in-2 chance of inheriting the faulty copy and a 1-in-2 chance of inheriting the working copy. It is like tossing a coin for each pregnancy. The chance is the same for every child, and for sons and daughters alike. It does not skip a generation, although a family history can look “quiet” if relatives died young from other causes, the family is small, or the gene change caused milder disease in earlier generations.

Most people with Li-Fraumeni syndrome inherited it from a parent. However, in about 7–20% of people, the change is new and started with them. This is called a de novo change. In that situation, the parents usually do not carry it, and the chance for brothers and sisters is low. Brothers and sisters are still offered testing because a parent can rarely carry the change in only some cells, including egg or sperm cells, without it showing up in a blood test.

Once the family’s TP53 change is known, testing relatives becomes simple and accurate. This step-by-step testing of relatives is called cascade testing:
–Parents, brothers, sisters, and children first
–Wider family next

Because some Li-Fraumeni cancers occur in infancy and early childhood, and screening begins from birth, guidelines support testing at birth (using cord blood) or soon after. Include older children and teenagers in the discussion and ask for their agreement.
A relative who tests negative for the known family change does not have Li-Fraumeni syndrome and cannot pass it on. Their cancer risk is generally similar to that of the general population. If the family change has not been found, a negative test in a relative cannot rule out the condition, and screening decisions need a genetics team’s guidance.

[Genetic Counselor]

The biggest clue to Li-Fraumeni syndrome is the pattern of cancers in a family: several relatives with cancer, cancers at unusually young ages, uncommon childhood cancers, or one person with more than one separate cancer. Doctors use published criteria to decide when TP53 testing is advised. In plain terms, testing is usually recommended when:

–A classic family pattern is present
–A person diagnosed with a sarcoma before age 45 has a parent, brother, sister, or child with any cancer before age 45, and another close relative with any cancer before age 45 or a sarcoma at any age.
–A core cancer appears young, with a similar cancer in a close relative
–A person has one of the five core cancers (breast before menopause, sarcoma, bone cancer, brain tumor, or adrenocortical carcinoma) before age 46, and a close relative had a core cancer before age 56 or had more than one cancer.
–One person has several cancers
–A person has had more than one separate cancer, two of them from the core group, with the first before age 46.
–Certain cancers appear at any age, even without a family history Adrenocortical carcinoma, choroid plexus tumor (a rare brain tumor in children), or a specific type of rhabdomyosarcoma.
–Breast cancer before age 31

This alone is reason to consider testing.

Testing is done on a blood or saliva sample. The laboratory reads the full TP53 gene and checks for missing or extra pieces. TP53 is often tested as part of a larger hereditary cancer panel that also looks at genes such as BRCA1, BRCA2, and CHEK2, which can cause overlapping family patterns.

Not every family that fits the pattern will have a TP53 change found. In that case, relatives are still considered at increased risk and should discuss screening with a genetics team.

[Genetic Counselor]

Li-Fraumeni syndrome is an inherited condition that greatly raises a person’s chance of developing cancer, often at a young age and sometimes more than once. It is not a single type of cancer. Instead, it is a built-in weakness in the body’s natural defense against cancer.

That defense depends on a gene called TP53. The protein made by TP53 (called p53) is often described as the “guardian of the genome.” Every day, the DNA inside our cells picks up small errors and damage. The p53 protein acts like a quality inspector on a factory line. When it spots damage, it stops the cell from dividing, calls in repairs, and, if the damage is too great, instructs the cell to destroy itself. This prevents damaged cells from growing out of control.

Most people have two working copies of TP53 in every cell. A person with Li-Fraumeni syndrome is born with one working copy and one faulty copy (called a pathogenic variant). One working copy still does most of the job. But if that remaining copy is damaged in a particular cell during life, the inspector is gone, and that cell can more easily turn into a cancer. Because p53 guards almost every tissue in the body, the cancers can appear in many different organs. This is why one family may have a child with a bone tumor, a young mother with breast cancer, and an uncle with a brain tumor, all caused by the same gene change.

Five cancers make up most Li-Fraumeni-related tumors:
–Breast cancer
-Soft-tissue sarcomas
-Osteosarcoma
-Brain tumors
-Adrenocortical carcinoma
-Other cancers are also more common, including leukemia (blood cancer), bowel, stomach, lung, pancreas, prostate, and skin (melanoma) cancers.

[Genetic Counselor]

Both are valid choices. The right one depends on cost, access, timing, and what you want to know.

• Non-Invasive Prenatal Testing: This is the most accurate screening test for Down syndrome, Edwards syndrome, and Patau syndrome. It finds about 99 in every 100 babies with Down syndrome and gives far fewer false alarms than the quadruple marker test. It can be done from 10 weeks and at any time after. It is more expensive, and sometimes returns a “no result”, which needs follow-up. The Society for Maternal-Fetal Medicine does not recommend routine screening for rare microdeletions with this test, and advises that screening for sex chromosome differences should be optional.
• Quadruple marker test: This is less expensive and widely available across India. It detects fewer affected babies and gives more false alarms. Its main advantage is the alpha-fetoprotein measurement, which also screens for open neural tube defects.

Neither test can:
• Diagnose a condition. Only amniocentesis or chorionic villus sampling can confirm a result.
• Check for single-gene conditions: Beta-thalassemia, sickle cell disease, spinal muscular atrophy, and cystic fibrosis need carrier screening of the parents, ideally before or early in pregnancy.
• Replace the anatomy scan: All pregnancies should have a detailed scan at 18 to 22 weeks, whichever screening test is chosen.
A consultation with a clinical geneticist can help you decide which test fits your pregnancy best and make sense of any result you have already received.

[Genetic Counselor]

A high alpha-fetoprotein does not mean the baby has a problem. The most common reasons are simple ones: the pregnancy is further along than thought, there are twins, or some of the baby’s blood has mixed with the mother’s. The main concern it screens for is an open neural tube defect. The American College of Medical Genetics and Genomics reports that alpha-fetoprotein screening picks up about 95 in every 100 babies with anencephaly and about 65 to 80 in every 100 with open spina bifida. Other causes include an opening in the baby’s belly wall and, rarely, congenital nephrotic syndrome, an inherited kidney condition caused by changes in genes such as NPHS1.

The next step is a detailed, targeted ultrasound by an experienced fetal medicine specialist. This finds most of these conditions directly. If the scan is unclear, doctors may do an amniocentesis and test the fluid for alpha-fetoprotein and an enzyme called acetylcholinesterase.
When the scan is normal, the high level is called “unexplained”. Most of these babies are healthy. There is a slightly higher chance of placenta-related problems later, such as high blood pressure in pregnancy, slow growth, or early birth, so extra growth scans are often advised.

A very low unconjugated estriol can, rarely, point to specific genetic conditions:
• Smith-Lemli-Opitz syndrome: An inherited condition in which the body cannot make enough cholesterol, caused by changes in both copies of the DHCR7 gene. Both parents are usually healthy carriers, with a 1-in-4 chance in each pregnancy. Amniotic fluid testing can confirm it.
• Steroid sulfatase deficiency: A condition affecting boys, caused by changes in the STS gene on the X chromosome. It mainly causes dry, scaly skin (X-linked ichthyosis) after birth, and can be linked with a slow start to labour.
Neural tube defects themselves are usually not caused by a single gene. They result from a mix of genetic and environmental factors, including low folate. After one affected pregnancy, the chance of another is about 2 to 3 in every 100. Taking a higher dose of folic acid, as prescribed by your doctor, before the next pregnancy lowers this chance substantially.

[Genetic Counselor]

No. A high-risk result means the chance is higher than the laboratory’s cut-off. It does not mean the baby has the condition. Because the test flags about 5 in every 100 pregnancies, and Down syndrome is much less common than that, most pregnancies with a high-risk result turn out to have a baby with normal chromosomes. Your exact number matters. A result of 1-in-20 is very different from a result of 1-in-200.
It is natural to feel worried. Because this result comes later in pregnancy, it helps to take the next steps without delay, so you have enough time to think and decide.

• Meet a genetic counselor or clinical geneticist. They will explain what your number means, check that the pregnancy dates used in the calculation were correct, and review your family history and scan findings.
• Option 1: Non-Invasive Prenatal Testing. This blood test looks at small fragments of DNA from the placenta in the mother’s blood. It is far more accurate than the quadruple marker test for Down syndrome, Edwards syndrome, and Patau syndrome, and carries no risk to the pregnancy. It is still a screening test, so a high-risk result from it also needs confirmation. Results usually take about a week.
• Option 2: Amniocentesis. This gives a definite answer by testing the baby’s own cells from the fluid around the baby. It can be done from 15 weeks onwards, so it is the usual diagnostic test at this stage of pregnancy. The chance of miscarriage from the procedure is small, about 1 to 3 in every 1,000 in experienced hands, and should be weighed against the chance found on screening.
• What the laboratory tests for: A rapid test for the common trisomies often gives results within a few days. Full chromosome results take longer. If the anatomy scan shows a structural difference, guidelines recommend chromosomal microarray, which finds smaller missing or extra pieces of chromosomes.

Some families choose further testing to prepare for the birth. Others choose not to test at all. Both are valid choices, and your care team should support whichever path you take.

[Genetic Counselor]

The test needs only a sample of the mother’s blood. The laboratory measures four substances made by the baby and the placenta:

• Alpha-fetoprotein: a protein made by the baby. It is often lower than usual in Down syndrome and higher than usual when there is an open neural tube defect.
• Unconjugated estriol: A hormone made by the baby and placenta working together. It is often lower in Down syndrome and Edwards syndrome.
• Human chorionic gonadotropin: The main pregnancy hormone. It is often higher in Down syndrome and lower in Edwards syndrome.
• Inhibin A: A hormone made by the placenta. It is often higher in Down syndrome. The triple marker test leaves this one out, which makes it less accurate.

Each level is compared with the usual level for that exact week of pregnancy. The result is shown as a “multiple of the median”. A value of 1.0 is exactly average, 2.0 is twice the average, and 0.5 is half. A computer then combines these values with the mother’s age to give a chance for each condition, such as “1-in-3,000” or “1-in-120”. Each laboratory uses a cut-off, often around 1-in-250 or 1-in-270. A chance higher than the cut-off is reported as “high risk” or “screen positive”.

Getting the details right matters a great deal. Hormone levels change quickly week by week, so the pregnancy dates should be confirmed by ultrasound. A wrong date is one of the most common reasons for a misleading result. The laboratory also needs your weight, whether you have diabetes treated with insulin, whether you smoke, whether the pregnancy is from in vitro fertilization, and whether you are carrying twins.

The quadruple marker test finds about 81 of every 100 babies with Down syndrome, while flagging about 5 in every 100 pregnancies as high risk. It finds about 60 to 80 of every 100 babies with Edwards syndrome. The triple marker test finds about 69 in every 100 babies with Down syndrome. A low-risk result is reassuring, but it does not rule out a chromosomal condition completely.

[Genetic Counselor]

Second trimester screening is a blood test done a little later in pregnancy, usually between 15 and 20 weeks (some laboratories accept samples up to 22 weeks). It estimates the chance that the baby has certain chromosome conditions or a problem with the development of the spine or brain. In India, it is most often called the “quadruple marker” or “quad marker” test. An older version with three markers, the “triple marker” test, is still used in some places.

Many families have this test because they first saw a doctor after 14 weeks and missed the window for first trimester screening. Others have it because first trimester screening or Non-Invasive Prenatal Testing was not available or affordable.

Second trimester screening looks mainly for three conditions:
• Down syndrome (trisomy 21) An extra copy of chromosome 21. It causes learning disability of varying degree, and some babies have heart or bowel differences.
• Edwards syndrome (trisomy 18) An extra copy of chromosome 18. It causes serious problems with the heart and other organs, and many pregnancies do not continue to birth.
• Open neural tube defects Conditions where the spine or skull does not close fully in early pregnancy. The two main types are open spina bifida (an opening in the spine) and anencephaly (where much of the brain and skull do not form). This is something first trimester screening does not check for.

Chromosome conditions usually happen by chance when the egg or sperm is formed, not because of anything the parents did. The chance of Down syndrome rises with the mother’s age, but it can happen in any pregnancy. This is why guidelines from the American College of Obstetricians and Gynecologists recommend offering screening to every pregnant person, whatever their age.
Second trimester screening is a screening test, not a diagnosis. It gives a chance, not a yes or no answer. It does not check for single-gene conditions such as beta-thalassemia, sickle cell disease, or spinal muscular atrophy. These need separate carrier screening of the parents.

[Genetic Counselor]

With diagnosis and treatment, the outlook for most people with long QT syndrome is very good. The risk of serious events is highest in childhood, the teenage years, and early adulthood, and treatment lowers it considerably. Most people live full lives, go to school, work, have families, and stay active.

Sports and exercise Earlier advice was to avoid all competitive sports. Current European guidelines now support shared decision-making. Many people who are well treated, have no recent symptoms, and follow precautions can take part in sport after assessment by a specialist in inherited heart rhythm disorders. Precautions include taking medicine regularly, keeping hydrated, and having a trained adult and an automated external defibrillator (a public-access shock device) nearby. Swimming carries particular risk in type 1 and should always be supervised.

Pregnancy Pregnancy itself is usually well tolerated. The higher-risk period is the 9 months after birth, especially in type 2, when broken sleep, stress, and sudden noises such as a crying baby combine. Beta-blockers should continue during pregnancy and after delivery. They are generally considered safe, and the baby’s growth and blood sugar are checked after birth. Pregnancy should be planned with the cardiologist and obstetrician together.

Regular follow-up Most people are seen every 6 to 12 months, and more often in children during growth spurts, when the medicine dose needs adjusting. Visits include an electrocardiogram, a review of the medicine dose, and sometimes an exercise test or heart monitor.

Family emergency plan Family members, teachers, and coaches should know how to do cardiopulmonary resuscitation (chest compressions) and where the nearest automated external defibrillator is. A medical alert card or bracelet helps emergency staff avoid unsafe medicines.

Emotional support A diagnosis can bring worry, especially after losing a relative. Genetic counseling and support from families living with the condition can help.

Long QT syndrome is a lifelong condition, but it is one where knowing early truly changes outcomes. Identifying relatives who carry the variant allows simple, effective steps to be taken before any problem occurs.

[Genetic Counselor]

Long QT syndrome is highly treatable. Treatment aims to prevent dangerous heart rhythms. The plan depends on the gene type, the length of the QT interval, age, sex, and whether the person has had symptoms. Doctors may use risk calculators that combine these details.

Beta-blocker medicines These are the main treatment. They calm the effect of adrenaline on the heart. Long-acting, non-selective beta-blockers such as nadolol or propranolol are preferred, because they are more protective than some others. They are usually taken for life. Missing doses or stopping suddenly can be dangerous. Beta-blockers are recommended for anyone with a prolonged QT interval, and are often advised for people who carry a variant but have a normal tracing.

Mexiletine for type 3 In some people with SCN5A-related long QT syndrome, this medicine can shorten the QT interval. It is started under close monitoring.

Implantable cardioverter-defibrillator A small device placed under the skin that detects a dangerous rhythm and delivers a shock to restore a normal beat. It is recommended after a cardiac arrest, and considered for people who still have events despite medicines.

Left cardiac sympathetic denervation A surgical procedure that cuts some of the nerves that release adrenaline to the heart. It is used when events continue despite medicines, or when beta-blockers cannot be taken.

Everyday precautions are just as important as treatment:

Avoid medicines that lengthen the QT interval These include certain antibiotics, antifungal medicines, anti-nausea medicines, antidepressants, antipsychotics, and some heart medicines. Always tell every doctor and pharmacist about the diagnosis. The CredibleMeds website keeps an up-to-date list.

Replace lost salts quickly Vomiting, diarrhoea, heavy sweating, fever, and some water tablets can lower potassium and magnesium, which raises the risk. Seek early treatment during these illnesses.

Reduce known triggers For type 1, supervised swimming is advised. For type 2, avoid sudden loud alarms and phone ringtones at night.

Consultation with geneticist is required to derive a targeted clinical care depending on an individuals clinical and genetic report.

[Author]

Posts